Interleukin 6 (IL-6) is a pleiotropic cytokine with many physiological functions. The present study was designed to determine the expression of IL-6 and its receptor (IL-6R) in human gastric and colorectal cancers. Nine gastric-and nine colorectal cancer cell lines were analysed. The IL-6 gene was expressed in two gastric cancer cell lines and one colorectal cancer cell line; however, most of the cancer cell lines studied expressed the IL-6R gene. The level of IL-6 secretion in the gastric cancer cell lines correlated with the level of soluble IL-6R secretion, and was significantly higher (< ~100 pg/ml) than the level of IL-6 secretion in the colorectal cancer cell lines (< ~50 pg/ml). These results suggest that IL-6 may act in a paracrine fashion rather than an autocrine fashion in these cell lines.
Introduction
Interleukin 6 (IL-6) is a multifunctional cytokine involved in immune responses, immunoglobulin production and haematopoiesis. 1 The IL-6 gene is expressed in a wide range of cell types, including fibroblasts, endothelial cells and various types of tumour cells. 2 IL-6 plays an important role in the pathogenesis of various diseases such as Castleman's disease and some autoimmune diseases. 3, 4 The IL-6 receptor (IL-6R), an 80 kDa glycoprotein, is expressed on the surface of lymphoid cells, but its gene is also expressed in non-lymphoid cells including tumour cells, in accordance with the multifunctional properties of IL-6. 5 In addition, a soluble IL-6R (sIL-6R) is secreted by cells into the extracellular space; this binds IL-6 and mediates IL-6 functions via the gp130 ligand in the cell membrane. 6 Interleukin 6 and IL-6R expression at gene or protein level have been reported in haematopoietic and non-haematopoietic human malignant cells in acute leukaemia, myeloma, melanoma, and lung and prostatic cancers. 7 -10 In these cells, the IL-6-IL-6R-gp130 complex has been demonstrated in vitro to directly enhance cell growth in an autocrine or a paracrine fashion, with its activities depending on the cell type. 11, 12 A few in vitro and in vivo studies have examined IL-6 expression in gastrointestinal cancers, 13 -15 but co-expression of both IL-6 and IL-6R in these tumours remains undetermined. The present study was designed to examine the expression of IL-6 and IL-6R in various human gastric and colorectal cancer cell lines.
Materials and methods

CELL LINES
Nine human gastric cancer cell lines and nine colorectal cancer cell lines were obtained from the Japanese Cancer Research Resources Bank (JCRRB; Tokyo, Japan) and the RIKEN Cell Bank (Ibaragi, Japan). All the cell lines were cultured in RPMI 1640 medium (Gibco BRL, Grand Island, New York, NY, USA) supplemented with 10% fetal calf serum (Gibco BRL), 4% L-glutamine and 80 mg/l kanamycin sulphate (Meiji Seika, Tokyo, Japan) in a humidified incubator (5% CO 2 at 37°C).
RNA EXTRACTION AND REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION
Total RNA from cultured cells was isolated using the guanidine isothiocyanate method. 16 After reverse transcription of 0.5 µg of total RNA, the target sequences of the genes for IL-6, IL-6R, gp130 and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) (as an internal control) were amplified for 30 cycles with specific primers using the protocol recommended by the manufacturer (RNA PCR kit, TaKaRa Shuzo, Shiga, Japan). The primers used were: human IL-6 and IL-6R genes, Cytokine Probes 5856-1 and 5871-1 (Clontech Inc., Palo Alto, CA, USA); gp130 gene, 5'-primer nucleotide (nt) 251 to 276, and 3'-primer nt 866 to 841; 17 and G3PDH gene, 5'-primer nt 71 to 96, and 3'-primer nt 1030 to 1053. The cycling conditions used were denaturation at 94°C for 45 s, annealing at 60°C for 45 s and extension at 72°C for 2 min. The reaction products were separated on a 1.5% agarose gel. The gels were stained with ethidium bromide and exposed to Polaroid™ 665 films under ultraviolet light.
HUMAN IL-6 AND sIL-6R ENZYME-LINKED IMMUNOSORBENT ASSAY
Firstly, 4 × 10 4 cells from each cell line were cultured in a 25 cm 2 flask, and the cell supernatants harvested on the third day of culture, centrifuged to remove any particle materials and stored at 4°C. The enzyme-linked immunosorbent assay (ELISA) for IL-6 and sIL-6R was performed three times using human IL-6 and sIL-6R Quantikine kits (R&D Systems, Minneapolis, Minnesota, USA) in accordance with the protocol described in the kit manual.
FLOW CYTOMETRY FOR IL-6R
Adherent culture cells were detached using Ca 2+ -and Mg 2+ -free ice-cold phosphate buffered saline (PBS) containing 5 mM ethylene diamine tetra-acetic acid (EDTA). The cells were suspended in buffer (1 × 10 6 cells/25 ml), incubated with biotinylated IL-6 (R&D Systems) for 60 min at 4°C, and washed twice to remove unreacted cytokine reagent. Cell suspensions were then incubated with 10 ml of avidin-fluorescein reagent for an additional 30 min at 4°C in the dark. The cells were washed twice to remove unreacted avidin-fluorescein, and resuspended in 0.2 ml of PBS for final flow cytometric analysis. Analysis was performed using a FACScan™ (Becton Dickinson, Mountain View, CA, USA) flow cytometer with Consort 30 software; data were livegated by size and propidium iodide uptake.
STATISTICAL ANALYSIS
Levels of secretion of IL-6 and sIL-6R were expressed as the mean ± SD of the three ELISAs undertaken for this cytokine and its receptor. Differences between groups were tested for statistical significance using the Mann-Whitney U-test, Spearman's rank correlation coefficient or paired Student's t-test. A two-tailed P < 0.05 denoted statistical significance.
Results
IL-6, IL-6R AND gp130 mRNA EXPRESSION IN CELL LINES
Interleukin 6, IL-6R and gp130 mRNA expression in the cultured cell lines were determined using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. In each group of nine cell lines tested, only two gastric cancer cell lines (MKN1 and GT3TKB) and one colorectal cancer cell line (CaR-1) expressed the IL-6 gene (Figs 1 and 2) . In contrast, most of the cell lines analysed expressed the IL-6R gene at various levels; only the GOTO line was negative (Figs 1 and 2 ). All the cell lines expressed almost equal levels of gp130 mRNA.
QUANTITATIVE ANALYSIS OF IL-6 AND sIL-6R SECRETION BY CULTURED CELLS
To determine the level of IL-6 and sIL-6R secretion by cultured cells, their concentrations in the cell supernatants were measured by ELISA 3 days after culture. Cell lines positive for IL-6 or IL-6R mRNA expression constitutively secreted IL-6 over 4 -5 days of culture, the concentration increasing with cell growth. Cell lines positive for the IL-6 gene on PCR analysis all secreted more than 50 pg/ml of IL-6 in the cell supernatant.
Gastric cancer cells secreted 40.0 ± 43.7 pg/ml of IL-6 and 87.6 ± 134.9 pg/ml of sIL-6R (Fig. 3A) . There was a clear correlation between the level of IL-6 and the level of sIL-6R secretion in each cell line (r = 0.851, P = 0.002). The GT3TKB cell line showed the highest level of IL-6 secretion, with a mean value of 119.9 pg/ml. Colorectal cancer cells secreted 24.0 ± 13.4 pg/ml of IL-6 and 188.1 ± 184.8 pg/ml of sIL-6R (Fig.  3B) . The IL-6 secretion level (< ~100 pg/ml) 71 K Matsuo, M Oka, K Murase et al. in the gastric cancer cell lines was significantly higher than the level secreted by colorectal cancer cell lines (< ~50 pg/ml). However, there were no significant differences in sIL-6R secretion between gastric and colorectal cancer cells.
IL-6 and IL-6R expression in cancer
FLOW CYTOMETRIC ANALYSIS OF IL-6R ON THE CELL SURFACE
Flow cytometric analysis was used to determine the presence of IL-6R on the cell surface. The gastric cancer cell line MKN1 expressed IL-6R on the cell surface as well as IL-6R mRNA, whereas the gastric cancer cell line GOTO did not express IL-6R mRNA or IL-6R on the cell surface ( Fig. 4 ).
Discussion
A number of human tumour cells express cytokines and/or their receptors, such as interleukins, interferons, transforming growth factors, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). 18 Conversely, some of these cytokines mediate host defences towards tumour cells through activation of the immune system or directly inhibit tumour cell growth in vitro and in vivo. Indeed, some cytokines have been used for cancer therapy, including gene therapy. 19, 20 However, in some instances, cytokines secreted by tumour cells, including IL-6, have been shown to enhance tumour progression in an autocrine fashion. 9, 14 Interleukin 6 could act as a stimulant or inhibitor of tumour cell growth in vitro; such activity is cell dependent and seems to correlate positively with concentration. 21, 22 On the other hand, Lopez et al. 23 reported coexpression of IL-6 and IL-6R at the gene and protein levels without apparent involvement in the proliferation of acute myeloid leukaemia cells. Baba et al. 13 established a human gastric cancer cell line that produced a high level of IL-6 as well as excessive G-CSF and GM-CSF, and demonstrated autocrine growth control by G-CSF. Growth and progression of gastrointestinal cancer cells may therefore be under the control of various cytokines other than IL-6.
Wu et al. 24 reported that serum IL-6 levels correlated with the progression of gastric cancer. In the present study, the IL-6 gene was expressed in two of the nine gastric cancer cell lines and one of the nine colorectal cancer cell lines, whereas most of the cell lines expressed the IL-6R gene. Tran-Thang et al. 25 reported that the eight colon cancer cell lines they studied did not express the IL-6 or IL-6R genes, whereas in our study, 73 K Matsuo, M Oka, K Murase et al. There is ample evidence to suggest that IL-6 and IL-6R play a role in the progression of colon cancer. De Vita et al. 26 reported that serum IL-6 levels in patients with gastrointestinal cancer correlated with cancer stage, and the levels decreased after tumour resection and increased after recurrence. These results suggest that IL-6 may be a suitable tumour marker for monitoring the response to treatment of patients with gastrointestinal tract cancers.
IL-6 and IL-6R expression in cancer
In the present study, we demonstrated that most of the cancer cell lines analysed concomitantly expressed IL-6 and sIL-6R, secreting them into the culture supernatants. To date, several soluble cytokine receptors have been identified, but their clinical significance is poorly understood. With regard to sIL-6R, it enhances the cytotoxic effects of IL-6 on myeloma cells and prostatic 10, 27 and sIL-R secreted by tumour cells can also act as an exogenous hormone towards tumoursurrounding cells such as fibroblasts. In fact, pathological examination of colorectal cancers often reveals desmoplastic features. 28 On the other hand, excessive sIL-6R secretion by tumour cells may increase their sensitivity to a small amount of exogenous or endogenous IL-6, whose effects are still undetermined in gastrointestinal cancer cells. Further studies are needed to elucidate the functional significance of cytokines and their receptors with regard to gastric and colorectal tumour cells.
In conclusion, our results suggest that IL-6 may act in a paracrine fashion rather than an autocrine fashion in gastrointestinal cancer cell lines, and the IL-6-IL-6R-gp130 cytokine complex may be involved in certain biological behaviours of these cancer cells.
